{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"55"}]}],"title":"Good Response - Week 76 (n=107, 61, 31)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"39"}]}],"title":"Moderate Response - Week 76 (n=107, 61, 31)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"}]}],"title":"No Response - Week 76 (n=107, 61, 31)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"56"}]}],"title":"Good Response - Week 128 (n=79, 47, 18)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"28"}]}],"title":"Moderate Response - Week 128 (n=79, 47, 18)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"17"}]}],"title":"No Response - Week 128 (n=79, 47, 18)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"EULAR28 categorizes clinical response based upon improvement since baseline in Disease Activity Score modified to include the 28-joint count (DAS28) and post-baseline DAS28. DAS28 consists of a composite score of the following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP, and Patient's Global Assessment of their Disease Activity (patient's global VAS). DAS28 scores range from 1.0-9.4. EULAR28 categories include: No Response (improvement in DAS28 of ≤0.6 units or post-baseline DAS28 score \\>5.1 with improvement by ≤1.2 units), Moderate Response (post-baseline DAS28 ≤5.1 with improvement by \\>0.6 units but ≤1.2 units or post-baseline DAS28 score \\>3.2 with improvement by \\>1.2 units), and Good Response (post-baseline DAS28 score ≤3.2 with improvement by \\>1.2 units).","groups":[{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"4 mg LY3009104 QD - Parts C and D"},{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.\n\nDose escalation criteria: ≥ 6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"},{"description":"Received 8 mg LY3009104 QD in Parts A, B and C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"}],"paramType":"NUMBER","populationDescription":"All participants who received study drug in Parts C and D and had EULAR28 evaluated at analysis time points. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 76 and 128","title":"Percentage of Responders According to EULAR28 Baseline Through Weeks 76 and 128","type":"SECONDARY","unitOfMeasure":"percentage of participants"}